These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35751140)

  • 41. TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Marvin-Peek J; Mason EF; Kishtagari A; Jayani RV; Dholaria B; Kim TK; Engelhardt BG; Chen H; Strickland S; Savani B; Ferrell B; Kassim A; Savona M; Mohan S; Byrne M
    Transplant Cell Ther; 2023 Jun; 29(6):390.e1-390.e10. PubMed ID: 36906277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.
    Quesada AE; Montalban-Bravo G; Luthra R; Patel KP; Sasaki K; Bueso-Ramos CE; Khoury JD; Routbort MJ; Bassett R; Hidalgo-Lopez JE; Zhao C; Lin P; Loghavi S; Ok CY; Kadia T; DiNardo CD; Kantarjian H; Garcia-Manero G; Kanagal-Shamanna R
    Mod Pathol; 2020 Sep; 33(9):1678-1689. PubMed ID: 32238878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
    Steensma DP; Wermke M; Klimek VM; Greenberg PL; Font P; Komrokji RS; Yang J; Brunner AM; Carraway HE; Ades L; Al-Kali A; Alonso-Dominguez JM; Alfonso-Piérola A; Coombs CC; Deeg HJ; Flinn I; Foran JM; Garcia-Manero G; Maris MB; McMasters M; Micol JB; De Oteyza JP; Thol F; Wang ES; Watts JM; Taylor J; Stone R; Gourineni V; Marino AJ; Yao H; Destenaves B; Yuan X; Yu K; Dar S; Ohanjanian L; Kuida K; Xiao J; Scholz C; Gualberto A; Platzbecker U
    Leukemia; 2021 Dec; 35(12):3542-3550. PubMed ID: 34172893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance.
    Song J; Hussaini M; Qin D; Zhang X; Shao H; Zhang L; Gajzer D; Basra P; Moscinski L; Zhang H
    Am J Clin Pathol; 2020 Jun; 154(1):48-56. PubMed ID: 32112088
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
    Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
    Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
    Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
    Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. m
    Cieśla M; Ngoc PCT; Muthukumar S; Todisco G; Madej M; Fritz H; Dimitriou M; Incarnato D; Hellström-Lindberg E; Bellodi C
    Mol Cell; 2023 Apr; 83(7):1165-1179.e11. PubMed ID: 36944332
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
    Malcovati L; Cazzola M
    Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetics of therapy-related myelodysplasia and acute myeloid leukemia.
    Pedersen-Bjergaard J; Andersen MK; Andersen MT; Christiansen DH
    Leukemia; 2008 Feb; 22(2):240-8. PubMed ID: 18200041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Significance of SF3B1 Mutations in Myeloid Neoplasms.
    Gajzer DC; Yeung CCS
    Clin Lab Med; 2023 Dec; 43(4):597-606. PubMed ID: 37865505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
    Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J
    Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis.
    Li F; Qin T; Li B; Qu S; Pan L; Zhang P; Sun Q; Cai W; Gao Q; Jiao M; Li J; Ai X; Ma J; Gale RP; Xu Z; Xiao Z
    Leukemia; 2024 Jun; 38(6):1334-1341. PubMed ID: 38714876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
    Wang H; Zhang N; Wu X; Zheng X; Ling Y; Gong Y
    Ann Hematol; 2019 Dec; 98(12):2629-2639. PubMed ID: 31754743
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome.
    Rujirachaivej P; Siriboonpiputtana T; Rerkamnuaychoke B; Magmuang S; Chareonsirisuthigul T; Boonsakan P; Petvises S; Sirirat T; Niparuck P; Chuncharunee S
    Asian Pac J Cancer Prev; 2018 Jul; 19(7):1825-1831. PubMed ID: 30049194
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A variant erythroferrone disrupts iron homeostasis in
    Bondu S; Alary AS; Lefèvre C; Houy A; Jung G; Lefebvre T; Rombaut D; Boussaid I; Bousta A; Guillonneau F; Perrier P; Alsafadi S; Wassef M; Margueron R; Rousseau A; Droin N; Cagnard N; Kaltenbach S; Winter S; Kubasch AS; Bouscary D; Santini V; Toma A; Hunault M; Stamatoullas A; Gyan E; Cluzeau T; Platzbecker U; Adès L; Puy H; Stern MH; Karim Z; Mayeux P; Nemeth E; Park S; Ganz T; Kautz L; Kosmider O; Fontenay M
    Sci Transl Med; 2019 Jul; 11(500):. PubMed ID: 31292266
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.
    Obeng EA; Chappell RJ; Seiler M; Chen MC; Campagna DR; Schmidt PJ; Schneider RK; Lord AM; Wang L; Gambe RG; McConkey ME; Ali AM; Raza A; Yu L; Buonamici S; Smith PG; Mullally A; Wu CJ; Fleming MD; Ebert BL
    Cancer Cell; 2016 Sep; 30(3):404-417. PubMed ID: 27622333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.